Cases of coexistent LA and anti-FII antibodies [4]
| No. | Age (years) | Gender | Underlying conditions | FII:C (%) | Anti-FII antibodies | LA | Clinical presentation | Remarks | |
|---|---|---|---|---|---|---|---|---|---|
| IgG (AU/mL) | IgM (AU/mL) | ||||||||
| II-1 | 34 | F | RA | 4.6 | 344 | 6.8 | dRVVT, Staclot LA, SCT, and CMT positive | Hematoma | Positive for aPS/PT |
| II-2 | 48 | M | SLE/SjS | 10 | 271.1 | 33.1 | dRVVT, Staclot LA, and CMT positive | Ecchymosis and hematuria | Positive for aCL, aβ2GPI, and aPS/PT |
| II-3 | 13 | M | SLE | 12.1 | 430.7 | 5.5 | dRVVT, Staclot LA, SCT, and CMT positive | Ecchymosis | positive for aCL, aβ2GPI, and aPS/PT |
| II-4 | 2 | M | Infection | 18 | 37.1 | 5.6 | dRVVT, SCT, and CMT positive | Ecchymosis | Positive for aCL |
| II-5 | 4 | F | Infection | 35 | 15.2 | 140.8 | dRVVT, SCT, and CMT positive | Ecchymosis | Positive for aCL and aβ2GPI |
| II-6 | 22 | M | Non-hodgikin lymphoma | 39 | 33.8 | 3.7 | dRVVT, SCT, and CMT positive | Not applicable | None |
| II-7 | 85 | M | Colon cancer/infection | 48 | 33.1 | 3.9 | dRVVT, SCT, and CMT positive | Not applicable | Positive for aβ2GPI |
| II-8 | 6 | M | Infection | 53 | 107.5 | 14.3 | dRVVT, Staclot LA, and CMT positive | Ecchymosis and ematoma | Positive for aPS/PT |
| II-9 | 57 | F | Multiple myeloma | 55 | 27.1 | 62.9 | dRVVT, SCT, and CMT positive | Hemorage | Positive for aCL and aβ2GPI |
| II-10 | 2 | F | Infection | 57 | 370.6 | 12.7 | dRVVT, Staclot LA, and CMT positive | Not applicable | Positive for aβ2GPI |
Normal range: FII:C < 60%, anti-FII Ab-IgG < 24 AU/mL, and anti-FII Ab-IgM < 24 AU/mL. No.: patient number; FII:C: FII activity; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SjS: Sjogren syndrome; SCT: silica clotting time; CMT: APTT cross mixing test; aCL: anti-cardiolipin antibody; IgG: immunoglobulin G